Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDINALS: Phase 2 Study of PTC857 in Adult Subjects with Amyotrophic Lateral Sclerosis
2021-006511-29Phase 2Active
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing PTC857 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in ALSFRS-R at 24 weeks. Started Jun 2022; status: active.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-006511-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006511-29.